A recent securities class action lawsuit filed in a Connecticut federal court charges that Achillion Pharmaceuticals, Inc., and its CEO and CFO misled investors by failing in an adequate and timely fashion to disclose clinical information and FDA actions related to sovaprevir, an Achillion drug under study for the treatment of hepatitis infections. If the Connecticut-based pharmaceutical company’s ability to fend off the allegations of the Complaint turns on the relationship between the Company’s “disclosures” and drops in its stock price (as the plaintiff and his lawyers would like), the Company may have a problem. However, as M&A lawyers are learning in the context of garden variety shareholder litigation and appraisal rights litigation, one available defense may lie in the Company’s ability to demonstrate the long-term “fair” or “intrinsic” value of its stock. [Read more...]
Legal compliance risks and corporate governance issues facing pharma companies.
Subscribe
Recent Posts
- Nursing Home “Worthless Services” Theory Can’t Support FCA Liability
- Parallel Misbranding Exception To PLIVA/Bartlett Is No Substitute For A New Rule From FDA
- FDA’s Social Media Guidance and the First Amendment – the Next Frontier
- Pharmarisc Is Back
- The Patent Troll Threat To Pharmaceutical Companies
Follow Me On Twitter
Blogroll
- Jose P. Sierra on LinkedIn
- Laredo & Smith, LLP
© 2012 · PharmaRisc.com · The ideas and opinions on this blog are my own as of the time of posting, have not been vetted with the firm or its clients, and do not represent the positions of the firm, its other lawyers, or any of its clients. None of these posts is intended as legal advice and if you need a lawyer, you should hire one. If you make a comment on the post, the comment will become public and beyond your control to change or remove it.